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ABSTRACT
Approximately 10% of all neonates are born small for gestational age (SGA) and current
feeding approaches increase adiposity and the risk of developing metabolic disorders, such as
obesity and diabetes. This study determined if supplementing formula with a combination of
leucine, medium chain triglyceride oil, and krill oil would promote gain of lean body mass using
newborn SGA term pigs as a model for SGA infants. At birth, SGA pigs have relatively smaller
livers and spleens (g/kg) than appropriate for gestational age (AGA) pigs and have higher serum
values for alanine aminotransferase, creatine kinase, and lactate dehydrogenase. Newborn SGA
pigs were randomly assigned to experimental and placebo groups and fed formula with and
without the supplement for 20 days. Placebo pigs tended to have greater body weight
(p<0.0734) due to significantly higher fat mass (p<0.02) and percent fat (p<0.05), and larger
livers. The present findings validate the concept an experimental supplement can improve body
composition of SGA term pigs and may decrease the risk of SGA neonates developing obesity
and metabolic abnormalities.
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INTRODUCTION
Background
Infants that are ≥35 weeks of gestation and <10th percentile on the Fenton Growth Chart,
excluding constitutional smallness are defined as small for gestational age (SGA).
Approximately 10% of all births are affected by SGA(Tudehope, Vento, Bhutta, & Pachi, 2013).
Intrauterine growth retardation (IUGR) is a clinical definition that applies to neonates born with
characteristics of malnutrition and in-utero growth retardation, irrespective of their birth weight
percentile (Sharma, Shastri, & Sharma, 2016). Therefore, SGA and IUGR are not synonymous.
Being born SGA does not necessarily mean IUGR has occurred and infants who are IUGR are
not necessarily SGA at birth (Iyengar et al., 2016).
Postnatal development of SGA infants is associated with higher risk of metabolic and
physiological abnormalities and growth retardation, leading to short stature and obesity in
adulthood, and increased risk of cardiovascular disease (CVD), and type two diabetes mellitus
(T2DM) (McIntire, Bloom, Casey, & Leveno, 1999). Due to impaired growth of the brain stem
and cerebellum, neurobehavioral and neurocognitive difficulties are common among SGA
infants. In later life, this can lead to speech retardation, slower sensory development, and
delayed motor development (Lundgren & Tuvemo, 2008; Sanz-Cortes, Egana-Ugrinovic, Zupan,
Figueras, & Gratacos, 2014; Sommerfelt et al., 2000).
There have been many attempts to correct impaired growth of SGA infants by ensuring
adequate nutrient intake. However, the compromised digestive functions of SGA infants
complicate establishing a balance between providing a dietary intervention that promotes catchup growth without overfeeding and causing intolerance. The most common approach is
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providing SGA infants with nutrient-enriched formulas with high-protein and/or high energy to
improve growth rate and nitrogen retention (Premji, Fenton, & Sauve, 2006).
The higher protein intake can potentially accelerate weight gain and nitrogen accretion in
formula-fed hospitalized infants, indicating enhanced postnatal growth. However, the high
protein intake does pose risks. The other widely used strategy of increasing energy intake tends
to increase weight gain as fat accretion (Fenton, Premji, Al‐Wassia, & Sauve, 2014). Considering
the special needs of SGA infants, nutritional interventions during the neonatal stage should focus
on promoting postnatal growth in lean body mass without causing potential metabolic problems
and the excessive accumulation of fat that increases the risk of childhood and adult obesity
(Fenton et al., 2014). Therefore, it is essential to provide appropriate amounts of protein and
energy in formulas fed to SGA infants, instead of simply providing more protein or energy.
In conclusion, there is a large and increasing population of SGA infants that are at risk of
intellectual deficits and abnormal metabolic and physiological development later in life.
Improving nutrition support of SGA infants has the potential to promote growth and
development that will improve outcomes and lifelong health and well-being.
Consequences of being born SGA
a) Postnatal patterns of growth
During first two years of postnatal life, SGA infants experience catch–up or sometimes
referred to compensatory growth. This specific growth type is exhibited by low birth weight
premature and term SGA infants and is characterized by dramatically increased weight gain
during the first 24 months of age. The rapid growth involves compensatory metabolic
mechanisms that promote fast weight gain, and results in SGA infants achieving 50-75 growth
and weight percentiles by the age of two years (Hwang, 2014). There are two types of catch-up

2

growth depending on the outcome: complete and incomplete. Incomplete catch-up growth
predisposes residual height deficits in childhood and adulthood. Complete catch-up growth refers
to an absence of growth deficits in adulthood. SGA infants are more likely to undergo
incomplete catch-up growth that leads to permanent short stature (Cho & Suh, 2016; Karlberg &
Albertsson-Wikland, 1995; Lee, Chernausek, Hokken-Koelega, & Czernichow, 2003; Leger,
Limoni, Collin, & Czernichow, 1998; Leger, Noel, Limal, & Czernichow, 1996; Wit & Boersma,
2002).
There are a variety of factors influencing the intensity of catch-up growth such as
hypersecretion of growth hormone (GH) (Leger et al., 1996) , initial birthweight, birth length
relative to gestational age, genetic factors relating to parental height and weight (Wit & Boersma,
2002) , and nutrition. The inability of many SGA infants to achieve complete catch-up growth
and have permanent short stature has been attributed to the diminished sensitivity of
somatotrophic cells and resistance to pituitary GH associated with immaturity of the GH receptor
(Lee et al., 2003; Leger et al., 1998).
There are two major hypotheses that have been proposed to explain the mechanism of
catch-up growth:
b) Neuroendocrine hypothesis
Despite a lack of experimental evidence (Leger et al., 1998; Leger et al., 1996; Wit &
Boersma, 2002), some have speculated the existence of a central mediator – possibly located in
hypothalamus – for sensing actual body size and comparing it to the expected size for the current
age. When the expected body size appropriate for a specific age is reached, the intensity of
catch-up growth will decrease.
c) Growth plate hypothesis
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The alternative theory is that age is not the limiting factor for catch-up growth, but that
growth is limited by the intrinsic growth capacity of a tissue itself (Lee et al., 2003; Leger et al.,
1998; Wit & Boersma, 2002) . A modification of this theory is that catch-up growth involves a
delay in normal growth plate senescence. Specifically, during normal growth plate senescence,
the proliferative rate of the growth plate chondrocytes diminishes with each successive stem cell
cycle. Thus, growth plate senescence is not a function of time per se but rather a function of the
cumulative number of divisions the stem cells have undergone (de Wit, Sas, Wit, & Cutfield,
2013).
There is a strong correlation between catch-up growth during the neonatal period and
precocious puberty and metabolic syndrome later in life (Emons, Boersma, Baron, & Wit, 2005;
Lui, Nilsson, & Baron, 2011) . SGA infants tend to experience early onset of puberty compared
to appropriate for gestational age (AGA) infants.The precocious puberty leads to earlier fusion of
the growth plates and a shorter adult height (Li et al., 2016; R. Verkauskiene, Petraitiene, &
Albertsson Wikland, 2013). The pathophysiological mechanism underlying the short stature of
SGA is also attributed to advanced bone maturation concomitant with lower bone density and
earlier epiphyseal plate closing (Li et al., 2016; R Verkauskiene et al., 2007)
Catch-up growth of internal organs of SGA infants
a) Kidneys and renal function
Catch-up growth is a very sensitive period of neonatal and infant development and it
affects not just linear growth, but influences internal organs as well; including the negative
impact it has on development of the kidneys. Fetal kidney development continues from nine to
thirty-six weeks of pregnancy and after term birth, no new nephrons are formed. IUGR is
commonly associated with reduced kidney size and nephron number in early childhood (Schmidt
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et al., 2005) and SGA infants also have lower renal mass (Hoy, Hughson, Bertram, DouglasDenton, & Amann, 2005). These findings emphasize the vulnerability of the kidneys to IUGR
and being SGA (Hoy, Rees, Kile, Mathews, & Wang, 1999; Schmidt et al., 2005).
Nowadays, ultrasound visualization of kidney volume is the gold standard for evaluation
of renal size and development. Usually, overall kidney volume can be used to estimate kidney
mass and is proportional to glomerular number (Lackland, Bendall, Osmond, Egan, & Barker,
2000). A small kidney on ultrasound may imply low nephron mass, but increased kidney size
cannot be used to distinguish between normal growth and hypertrophy (Iyengar et al., 2016) .
Considering the impaired kidney growth in SGA infants, there is a need to focus on the
critical issue of nephron protection at birth, emphasizing the importance of regular monitoring of
glomerular filtration, not just reliance on ultrasound, to detect and prevent possible disturbances
in renal function.
b) Catch-up growth of brain structure and neurodevelopment in SGA infants
Head circumference is considered a reliable measure of estimated brain weight and brain
development during the first two years of life. Head circumference catch-up growth in SGA
neonates is usually completed by the age of two years old (Geelhoed et al., 2009). However,
exposure of the fetal brain to adverse factors, such as IUGR during a critical period of
development can have lifelong consequences. There is increasing evidence of brain
reorganization not just in severely low birth weight infants, but also in SGA infants close to term
(Brandt, Sticker, & Lentze, 2003). Differences in brain metabolism, microstructure and cortical
sulcation pattern have been reported in term SGA infants (Sanz-Cortes et al., 2014), including
significantly larger pontine and medullar measurements compared to AGA infants. Moreover,
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fetal MRI texture analysis shows cerebellar differences in SGA infants (Sanz-Cortes et al.,
2013).
The cerebellum plays a crucial role not just in motor development, but also learning,
memory, cognition, and behavior (Baillieux, De Smet, Paquier, De Deyn, & Mariën, 2008). The
brain structural differences in SGA infants coincide with neurobehavioral differences, such as
delayed neurodevelopment and lower intellectual performance. The cognitive impairment can be
largely attributed to a higher incidence of neurologic abnormalities in the SGA neonates (CruzMartinez et al., 2009).
There are many factors contributing to intellectual status of infants such as
socioeconomic status, as well as behavioral characteristics of inattention and anxiety. It has also
been shown that there is a correlation between the severity of IUGR, head circumference and
academic achievements. Infants with signs of placental hypoperfusion and IUGR are at greater
risk of abnormal neurodevelopmental outcomes throughout life: from early infancy to the
adulthood (McCarton, Wallace, Divon, & Vaughan, 1996).
Children who do not achieve full head circumference catch-up growth have lower levels
of intellectual performance and show lower intelligence quotient (IQ) levels (Hack et al., 1991;
O’Keeffe, O’Callaghan, Williams, Najman, & Bor, 2003). At the age of eight years, infants with
smaller head circumference and lower birthweight are more likely to have lower IQ scores and
even signs of neurological abnormalities. There are also differences in academic achievement
and professional attainment compared with adults who were born with AGA weight (Hack et al.,
1991; Larroque, Bertrais, Czernichow, & Léger, 2001; Lundgren, Cnattingius, Jonsson, &
Tuvemo, 2001).Low birth weight also increases risk for the development schizophrenia (Rifkin,
Lewis, Jones, Toone, & Murray, 1994; Wahlbeck, Forsén, Osmond, Barker, & Eriksson, 2001).
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Metabolic concerns contributing to SGA morbidity
Changes in the growth hormone/insulin-like growth factor (GH/IGF) axis have been
reported in children that were SGA infants. Notably, mean serum levels of IGF1 and IGFbinding protein-3 of neonatal SGA infants are about one standard deviation lower than those of
AGA neonates (Ong, Ahmed, Emmett, Preece, & Dunger, 2000).
Concomitant insulin resistance has been reported in SGA infants and is considered to
predispose for metabolic disorders such as obesity, cardiovascular disease CVD, and T2DM
(Hofman et al., 1997; Soto et al., 2003).
SGA infants show signs of insulin resistance in early infancy and throughout childhood,
depending on body weight and body length. There is a direct correlation between
anthropometric measurements in SGA infants and insulin sensitivity and secretion: infants with
lower body mass and lower body length during infancy show more signs of insulin resistance
(Barker et al., 1993).
There are several theories for the development of insulin resistance in SGA infants. One
of the first, “Small baby syndrome,” suggests that undernutrition and unfavorable environmental
factors (maternal smoking, maternal undernutrition during pregnancy) program for future
metabolic abnormalities in later life (Neel, 1962).
Another theory called the Thrifty Genotype Theory was proposed in 1962 and states that
genes promoting survival and growth of the fetus in an unfavorable prenatal environment also
promote the development of insulin resistance in a favorable postnatal environment (Prentice,
Rayco-Solon, & Moore, 2005; Vu-Hong et al., 2006). This theory suggests that under the
influence of intrauterine malnutrition, SGA infants allocate the limited energy and nutrients to
vital organs at the expense of somatic growth and less important organs, such as pancreas. This
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leads to reduced β-cell mass and as a result, to insulin resistance and metabolic disorders.
Although not supported by further research, more than changes in patterns of gene expression
lead to insulin resistance and metabolic abnormalities (Cianfarani, Germani, & Branca, 1999).
Despite numerous studies of the relationship between insulin resistance and being SGA,
the reasons and mechanisms leading to insulin resistance remain unclear. Regardless, the early
onset of insulin resistance in SGA infants can be a potential marker for early identification and
intervention to reduce the risk of developing metabolic syndromes in adulthood.
Adiposity that develops in early childhood and adulthood of former SGA infants is
another keystone of insulin resistance and metabolic syndrome (Jaquet et al., 2005). Being small
for gestational age is associated with less lean body mass and a higher risk of sarcopenia
(Ylihärsilä et al., 2007). The ratio of lean body mass relative to fat mass is initially altered in
SGA infants that suffered IUGR. SGA infants display a peculiar growth pattern of adiposity.
Although severely reduced at birth (Biosca et al., 2011; Enzi, Zanardo, Caretta, Inelmen, &
Rubaltelli, 1981), adiposity dramatically increases during the catch-up growth period, as
evidenced by the noticeably increased body mass index (BMI) during infancy (Ezzahir et al.,
2005; Jaquet, Leger, Tabone, Czernichow, & Levy-Marchal, 1999). The higher BMI persists
throughout childhood into adulthood, increasing vulnerability for developing metabolic
disturbances (Ibáñez, Lopez-Bermejo, Diaz, & de Zegher, 2011). In the early neonatal period,
SGA infants are more prone to accumulate fat mass, specifically abdominal fat. This results in a
greater central fat distribution compared to AGA infants (Fenton et al., 2014; Jaquet et al., 1999)
and lowers the ratio for lean relative to fat mass, and more so when nutrient support does not
meet the specific dietary needs of SGA infants 54.

8

Not only the extent, but also the dynamic changes during childhood in adiposity that
occur in individuals who were born SGA may play a crucial role in determining the long-term
metabolic outcomes (Fenton et al., 2014). After finishing catch-up growth period, SGA infants
not only are characterized by having a higher percentage of fat body mass compared to AGA
infants, but also have elevated levels of insulin, leptin, and significantly lower levels of
adiponectin and exhibit dyslipidemia (Hediger et al., 1998).
Overview of possible nutritional interventions
There have been many attempts to correct impaired growth of SGA infants and provide
adequate nutrient intake. Due to compromised digestive functions, it is very hard for the
physician to choose a dietary intervention that establishes a balance between normal nutrient
intake and overfeeding. The difficulty in providing adequate nutritional support for SGA
newborns is one of the main reasons for postnatal growth deficits.
The most common approach of nutritional support for SGA infants is feeding highprotein/high energy formulas to improve the growth rate and nitrogen retention (20% energyenriched and 40% to 60% more protein and minerals than term formulas). The goal is to
increase body weight and length and head circumference growth during the first 18 months of
age (Fenton et al., 2014). However, it has been stated that the major effect of higher energy
intake (142 kcal/d vs. 120 kcal/day) in LBW infants was increased fat accretion. Studies using
animal models show that protein/calorie malnutrition affects the utilization and deposition of
protein and fat (Feillet-Coudray et al., 2009).
High nutrient intake in IUGR pigs causes abnormal immune functions, via lower serum
concentrations of cytokines such as tumor necrosis factor and interleukin (IL) - 1β (Pollock,
1989). Furthermore, the aggressive nutritional strategy promotes excessive oxidative stress
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(Décordé et al., 2009; Guoyao & Morris, 1998; Pollock, 1989; Sanz-Cortés et al., 2013), which
potentially overwhelms the immature antioxidant system of SGA infants.
Another widely used approach for improving the health of SGA infants is selective
enrichment of infant formula with L- arginine, L-carnitine, branched-chain amino acids,
glutamine, polyunsaturated fatty acids and nucleotides. The intention is to provide nutrients that
will enhance growth and maturation without excessive protein and energy intake.
a) L-arginine supplementation
Arginine is a precursor not just for protein synthesis, but also of nitric oxide, urea,
polyamines, proline, glutamate, creatine and agmatine (Shah & Shah, 2007). Lower levels of
these metabolites when arginine intake is limited are considered to be contributing factors in the
pathogenesis of necrotizing enterocolitis (NEC). Correspondingly, supplementation with Larginine during the neonatal period lowers the risks of necrotizing enterocolitis and improves
protein synthesis (El-Shimi et al., 2015; Mitchell et al., 2014; Shah & Shah, 2007).
b) Glutamine – enriched formula
Glutamine (Gln) plays important roles in energy metabolism, maintains synthesis of
arginine, nucleotides, is involved with cell signaling, and is as a “conditionally essential” amino
acid. Gln supplementation (0.3 g/kg/day) of formulas can increase the growth rate of LBW
infants during first 4 months of life (Korkmaz, Yurdakök, Yigit, & Tekinalp, 2007). Moreover,
it increases enteral feeding tolerance in low birth weight infants and decreases duration of
hospital stay in neonatal intensive care units (NICU) (Kao et al., 2016; Neu et al., 1997; van den
Berg, van Elburg, Westerbeek, Twisk, & Fetter, 2005). However, Gln is unstable in solution,
which limits clinical use.
c) Leucine supplementation
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Recently, there has been increased interest in evaluating leucine and associated
metabolites as possible adjuncts to nutritional therapies to increase muscle protein synthesis and
growth. One such metabolite of leucine, β-hydroxy-β-methylbutyrate (HMB), enhances muscle
growth and improves muscle strength (Columbus, Fiorotto, & Davis, 2015; Torrazza et al.,
2010). Leucine itself increases anabolic rates through the mammalian target of rapamycin
(mTOR) pathway. This signaling pathway stimulates protein synthesis independent of activation
of the insulin signaling pathway. Extensive animal studies demonstrate beneficial effects of
leucine supplementation on metabolism (Columbus, Steinhoff-Wagner, et al., 2015; Gutbrod,
Wolke, Soehne, Ohrt, & Riegel, 2000; Manjarín et al., 2016; Torrazza et al., 2010).
d) Supplementation with long chain polyunsaturated fatty acids
The major long chain polyunsaturated fatty acids (LC-PUFA), like arachidonic acid
(20:4n-6, ARA), eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic acid (22:6n-3,
DHA), are essential nutrients for maintaining health, cognition, and development during fetal
and early postnatal life (Meldrum & Simmer, 2016). Therefore, dietary LC-PUFA
supplementation can be considered as an efficient strategy to recover the altered physiologic
composition of fatty acids of IUGR neonates (Birch et al., 2010; Birch et al., 2007).
Corresponding with this, DHA supplementation of infant formula at 0.32 % of total fatty acids
improves visual acuity. However higher amounts of supplemental DHA do not show further
improvement of visual acuity or any other health-related benefits (Innis, 2007). Although there
is no doubt that DHA is critical in the developing brain, the question of whether dietary DHA is
important during early neonatal human brain development remains unresolved (Gieling,
Schuurman, Nordquist, & van der Staay, 2011; Jasani, Simmer, Patole, & Rao, 2017).
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The pig as a model for improving nutrition support of small for gestational age
infants
Intervention studies with SGA human infants are extremely difficult due to obvious
ethical considerations. Furthermore, confounding factors of genetics, postnatal care, and health
status complicate interpretations of responses to nutrition support. In light of this, various animal
models have been used to understand the consequences of being SGA and to evaluate possible
interventions. Although rodent models are commonly used, it is difficult to translate findings to
SGA infants. Exemplary are the substantial differences in organ development and morphology
between rodents and humans.
In this regard, the domestic pig may be an excellent model (Aigner et al., 2010). Vital
organs for humans and pigs share similar anatomy, physiology, and patterns of development.
This includes the lungs, kidneys, heart, liver, and gastrointestinal tract. Like humans, the major
brain growth spurt in pigs extends from the late prenatal to the postnatal period. Gross
anatomical features, including gyral pattern and distribution of gray and white matter of the
neonatal piglet brain are similar to that of human infants (Dam, Juhl, Sangild, & Svendsen,
2017). Moreover, the size of neonatal pigs allows for neuroimaging using equipment designed
for human infants. Indeed, structural magnetic resonance imaging (MRI), functional MRI, and
positron emission tomography have all been conducted in pigs (Rigo et al., 1998). Finally, due
to their precocial nature, newborn pigs can be fed formula from birth, raised with relative ease,
and used in behavioral testing paradigms to assess learning and memory at an early age (Picaud
et al., 1999). Importantly, pigs born SGA have anomalies in organ size and maturation that
mimic those of SGA infants. Therefore, the neonatal pig is a highly tractable translational
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animal model that can be used to investigate SGA-associated disorders and potential
interventions.
Conclusion
Before providing nutritional interventions for SGA infants, neonatologists and
pediatricians must consider the risks associated with metabolic abnormalities,
neurodevelopment, and prevention of long-term consequences. Summarizing the existing
knowledge, we can conclude that due to metabolic abnormalities of SGA neonates, nutrition
strategies that are energy intensive or with high protein might not be optimal. There is a need to
consider the appropriate amount of protein and energy that are required by SGA infants to
support growth and development, instead of simply providing high protein or high energy
supplements.
MATERIALS AND METODS
Research objectives
Previous studies indicate that formulas supplemented with fatty acids and protein
dramatically increase weight gain. Additionally, SGA infants are prone to fatty acid deficiency,
specifically long chain omega-3 polyunsaturated fatty acids. Together, these findings led to the
concept of a multi-ingredient supplement for SGA infants. Krill oil was selected as a source of
essential polyunsaturated fatty acids (DHA and EPA) because of the increased level of
phospholipid rather than triglyceride. Medium- chain triglyceride (MCT) oil was chosen as a
ready source of energy to reduce catabolism of protein and amino acids, and the branched chain
amino acid leucine was included to activate the mTOR pathway and stimulate muscle protein
synthesis. The expectation is adding this supplement to existing infant formula or to expressed
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breast milk will improve growth by increasing lean body mass and promote organ development
of term SGA neonates.
Based on the existing knowledge, I tested the hypothesis that newborn term SGA pigs fed
for 20 days a formula (pig milk replacer) supplemented with krill oil, MCT oil, and leucine will
realize better growth as greater lean body mass and accelerated organ maturation compared with
siblings fed a placebo formula.
Aims
Aim 1: Determine whether supplementation improves growth and body composition
Aim 2: Determine if SGA pigs fed formula with the supplement experience accelerated
organ growth.
Study design
This study included four groups that are illustrated in figure 1. The first phase of the
study included two groups of 6 AGA pigs and 6 SGA pigs. These groups were examined to
determine initial differences between SGA and AGA pig within 12 h after birth at term. The
next phase involved obtaining newborn SGA pigs that were distributed to treatment and placebo
groups. All of the pigs originated from the same commercial producer, were of the same genetic
lineage, and were considered as specific pathogen free.

Initial groups
of SGA and
AGA

AGA n=6
Experimental
group
SGA n=6

Placebo
n=8
Treatment n=8

Figure 1. Study design
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Animal care and housing
All phases of the research involving animal use were performed in accordance with the
8th edition of the Guide for the care and use of Laboratory Animals and have been approved by
The University of Memphis Institutional Animal Care and Use Committee (IACUC).
The feeding trial used a total of 16 healthy newborn term SGA pigs of both sexes that
were obtained at <24 h of age with body weights of 600 to 1200 g. Based on average birth
weights, ~10% of newborn pigs are <1200 g and can be considered as SGA and therefore
relevant as models for SGA human infants. The newborn pigs were allowed to suckle the sow
after delivery until they were brought to University of Memphis (within 24 h after delivery) to
allow for acquisition of passive immunity. The pigs were randomly assigned to placebo and
treatment groups, and housed in pens that are located in facilities compatible with newborn pigs
and which we have used previously for such studies. The pens are 0.62 m x 1.2 m, have a slatted
floor to facilitate cleaning, and have a suspended infrared heating lamp.
All the pigs were fed a commercial milk replacer that meets the known energy and
nutrient requirements of suckling pigs (Table 1). This milk replacer does not induce necrotizing
enterocolitis and promotes good growth and health of newborn term pigs. After the pigs were
trained to drink from bottles with nipples they were be allowed to drink from a bottle feeder,
designed specifically for raising suckling pigs. The volume of formula voluntarily consumed by
each group was recorded. At each feeding, pigs were observed for activity and responsiveness,
general health status, and the cage was cleaned. The pigs were weighed twice each day: 12:00
and 18:00. The dietary intervention period was 20 days.
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Table 1. Composition of milk replacer
Guaranteed analysis
Crude protein
Crude fat
Calcium

Minimum
Minimum
Minimum
Maximum
Minimum
Minimum
Minimum

30.0 %
26.0 %
0.8 %
1.3 %
0.9 %
1 PPM
12.500 IU/LB

Phosphorus
Selenium
Vitamin A
Other:
Dried whey, Lactose, Dicalcium Phosphate, Potassium Chloride, Lecithin, Mineral oil,
Magnesium Sulfate, Ferrous Sulfate, Zinc Proteinate, Selenium Yeast, Vitamin E Supplement,
Ascorbic acid, Zinc Sulfate, L- Carnitine, Copper Proteinate, Biotin, Vitamin A Acetate,
Niacineamide, d-Calcium Pantonthenate, Vitamin D3 Supplement, Manganese Sulfate,
Vitamin B12 Supplement, Thiamine, Calcium Iodate, Folic acid
Dietary supplement composition
The treatment supplement added to the milk replacer contained functional nutrients, that
were hypothesized would promote growth, primarily as lean body mass and encourage growth
and functional development of vital organs. With the supplement added, each liter of the
formula contained 3.3 ml of krill oil (7.7 g/100 g DHA, 13.2 g/100 g EPA) 10 g of medium chain
triglyceride (MCT) oil (Caprylic acid 73.72%, Capric acid 26.16%, water 0.0048%, free fatty
acid 0.0066, other 0.1086 %), and 10 g of the amino acid leucine (76 mM). A preliminary study
using initial dosages of MCT and vegetable oil at 20 ml/L of prepared formula resulted in the
pigs developing steatorrhea, which was considered as a sign of lipid intolerance. The dosage of
MCT and vegetable oils was reduced to 10 ml/L of prepared formula, the symptoms of
intolerance were suppressed. The krill oil remained at 3.3 ml/L.
The placebo supplement was isonitrogenous by combining the same amounts of
vegetable oil blend (Caprylic acid 1.4%, Lauric acid 8.9%, Palmitic acid 20.8%, Stearic acid
3.7%, Vaccenic acid 37.1%, γ-Linolenic acid 1.5%, else 0.1 %) and alanine (6.8 g/L; 76 mM)
( Figure 2), (Table 2).
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Vegetable oil blend
10ml/L

Treatment

Placebo

Alanine 6,8 g/L

Leucine 10 g/L

MCT oil blend 11ml/L

Krill oil 3.3 ml/L

Figure 2. Composition of experimental diets. Placebo and treatment diets
Table 2. Composition of krill oil as reported by supplier
ω -3 (usually < 30g/100g)
Eicosapentanoic acid (EPA)
Docosahexanoic acid (DHA)
α - Linolenic acid
Stearidonic acid
ω -6
γ-Linoleic acid
Arachidonic
ω -9
Oleic acid
Other
Palmitic acid
Palmitoleic acid
Stearic acid

13.2
7.7
1.2
3
0.2
0.3
10.7
13.5
2.5
0.6

Sampling
Blood samples were collected prior to the necropsy on day 21 of study and distributed to
tubes containing either ethylenediaminetetraacetic acid (EDTA) for isolation of plasma or in
serum separator tubes. Plasma and serum samples were aliquoted into 1.5 ml microtubes and
stored at -80°C until analysis.
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Necropsy protocol
At conclusion of the feeding trial the pigs were sedated with telazol 0.2 ml/kg, imaged
using dual x-ray absorptiometry (DEXA) to assess the percentage of lean and fat body mass, then
anesthetized using isoflurane for intracardiac collection of blood before euthanasia (Euthasol; 1
ml per 4 kg)
After death, each pig was necropsied and internal organs were removed, observed,
weighed, and representative tissues fixed using 10% neutral buffered formaldehyde.
Serum and plasma were collected for general metabolic parameters such as: albumin,
alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST),
calcium, cholesterol, creatine kinase (CK), creatinine, glucose, lactate dehydrogenase (LDH),
triglycerides. The measurements were made using an Alfa Wasserman Vet Axcel blood
chemistry analyzer (Diagnostic Technologies, LLC)
Outcome measures
Dual energy x-ray absorptiometry (DEXA)
DEXA provides reliable measurements of bone density, fat and lean body mass, and has
been used to evaluate body composition of neonatal pigs and human (Picaud et al., 1999; Picaud,
Rigo, Nyamugabo, Milet, & Senterre, 1996). Hologic discovery Dual Energy X-ray
Absorptiometer were used to determine if the treatment supplement preferentially promotes
growth of lean body mass rather than adipose tissue.
Statistical analysis
SAS 9.4 was used to perform all statistical analyses of body weight, DEXA parameters,
and weights of brain, cerebellum, heart, lungs, liver, spleen, and pancreas.
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Aim 1: Determine whether supplementation improves growth and body composition.
Statistical analysis of obtained dataset was performed using the Wilcoxon signed-rank test, twotailed paired Student’s t-tests to evaluate if daily weight gain and daily supplement consumption
differed between the two groups (placebo and treatment).
Aim 2: Determine if SGA pigs fed formula with the supplement experience have
accelerated organ growth. The data were analyzed by Wilcoxon signed-rank test, two-tailed
paired Student’s t-tests.
For all comparisons, P-values less than 0.05 were considered as significant.
RESULTS
Analysis of initial groups of SGA and AGA pigs studies the first day of life
The initial groups of newborn SGA and AGA pigs (n=6 per group) were delivered to the
University of Memphis for immediate organ and tissue collection to determine if initial organ
weights and baseline differences existed between SGA and AGA piglets for weights of the
kidneys, liver, spleen, pancreas, lungs, heart.
Body weight analysis
As seen from figure 3, body weight of AGA group was significantly larger assessed via
Wilcoxon Signed-Rank test. Summary of weight statistics is presented in table 3.
Table 3. Summary of weight (grams) statistics in initial SGA and AGA groups
Group

Mean

Std. Deviation

AGA

1640

267.8

SGA

790

71.88

P-value

Extreme
Observations
t-test
Wilcoxon Min Max
score
1240 1998
<0.0001 0.0039
695

19

914

p <0.0001

Figure 3. Distribution of body weights for the initial groups of SGA and AGA groups
Organ weights
The liver and spleen were significantly larger in newborn AGA pigs. All organ weights were
normalized to body mass to account for differences in birth weights (g/kg body weight).
a) Spleen weight
Analysis of relative spleen weight (g/kg) showed that SGA pigs had significantly smaller
spleens [(AGA 1.6 ± 0.15 vs. SGA 1.23 ± 0.08, n=12; p=0.043)]. (Figure 4)
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p <0.043

Figure 4. Spleen weight g/kg of body weight for initial groups of SGA and AGA pigs
b) Liver weight
Analysis of liver weights determined that SGA group has significantly lower relative
liver weights (Figure 5) [(AGA 27.7 ± 8.7 vs. SGA 21.6 ± 1.92, n=12; p=0.03)].

p <0.03

Figure 5. Liver weight g/kg of body weight for initial groups of SGA and AGA
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c) Kidney weight. Kidney weight description is presented in table 4.
Table 4. Comparison of kidney weight (g/kg) between initial groups of SGA and AGA pigs
Group

Mean
kidney

Std.
Deviation
kidney

P-value
t-test

right

left

right

left

right

left

Wilcoxon
score
right left

AGA

0.004

0.005

0.002

0.003 0.58

0.5

0.63

SGA

0.0043 0.0044 0.001

0.63

0.003

d) Lung weight. Comparison of lung weights is presented in table 5.
Table 5. Comparison of lung weight (g/kg) between groups.
Group

Mean

Std.
Deviation

P-value
t-test
0.36

AGA

0.018

0.004

SGA

0.021

0.0058

Wilcoxon
score
0.336

e) Heart weight. Comparison of heart weights is presented in table 6.
Table 6. Comparison of heart weight (g/kg) between initial groups of SGA and AGA pigs
Group

Mean

Std.
Deviation

P-value
t-test
0.27

AGA

0.0097

0.00251

SGA

0.00843

0.0011

Wilcoxon
score
0.42

f) Table 7 reflects basic metabolic parameters in initial groups of SGA and AGA. There are
significant differences in LDH, ALT and CK.
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Table 7. Basic metabolic parameters AGA vs. SGA
Group

ALB
g/dL

ALP
U/L

ALT
U/L

AST
U/L

AGA
SGA
p-value

0.71
0.6
0.1

1318
1451
0.69

18
26
0.023

57.6
94.3
0.1

Ca
mg/
dL
8.3
9.1
0.1

Chol.
mg/d
L
44
48
0.6

CK
U/L

Creat.
mg/dL

LDH
U/L

TP
g/dL

192
773
0.01

0.7
1
0.1

430
865
0.0036

4.2
3.5
0.34

TG
mg/d
L
33
30
0.58

Analysis of experimental groups of SGA pigs after 20 days of feeding
A total of 16 newborn SGA piglets were delivered to the University of Memphis, were
randomly assigned to placebo or treatment groups, and were fed for 20 days milk replacer either
with the treatment supplement with leucine, MCT oil and krill oil or placebo supplement with the
vegetable oil blend and alanine.
On day 21 of the study the pigs were sedated, DEXA scans were made and blood was
collected before euthanasia and the collection of organs for measuring weight.
Body weight and weight gain analysis
Average body weight of placebo group was larger [(placebo 3417± 780.89 vs. treatment
2665± 725.9, n=16; p=0.06)], despite the fact that both groups were provided the same amount
of formula per day (150 ml/kg/day).
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p <0.06

Figure 6. Body weight (g) treatment group vs. placebo
Average daily weight gain for the placebo group was 98 g per day compared with 63 g
per day for the treatment group. These values corresponded with formula consumption per day of
708 ml per day in placebo group vs. 618 in treatment group. However, accurate assessments of
consumption were difficult because of spillage of formula by the pigs. Throughout the study,
treatment group pigs were more active and playful. The higher level of activity may have
contributed to the differences in weight gain.
Figures 6 and 7 display daily weight gain percentages between groups. Our findings
suggest that treatment group pigs gained less weight than placebo group pigs respectively to birth
weight: Placebo 7% vs. 4.99% in treatment group. Daily weight gain percentage over period
between groups is reflected in figure 7. As shown in figure 8 both groups had comparable weight
gains for the first week of feeding. Thereafter, the placebo group started to gain weight faster

24

than treatment group and this increased weight gain persisted throughout the third week of the
feeding period.
% of weight gain in 20 days
8%
7%
6%
5%
4%
3%
2%
1%
0%
Placebo

Treatment

Figure 7. Average weight gain percentage between groups. Data is represented as means ±
std. deviation.
% daily weight gain percentage
9%
8%
7%
6%
5%
4%
3%
2%
1%
0%
Treatment
days 1-10

Placebo
days 10-20

Figure 8. Comparison of weight gain during dietary intervention. Data is represented as
means ± std. deviation.

25

Weekly weight gain (g) between groups
4000
3500
3000

g

2500
2000
1500
1000
500
0

0

1

Treatment

2

3

Placebo

Figure 9. Weight gain (g) per week between groups
Organ weight analysis between groups.
a) Liver weight. The absolute and relative weight of the livers of placebo pigs were
significantly larger [(placebo 145.4 ± 21.36 g vs. treatment 89.4 ± 34.02 g, n=16;
p=0.0015)], [(placebo 44.2 ± 3.4 g/kg vs. treatment 33.0 ± 1.5 g/kg, n=16; p=0.001)]

p < 0.001

Figure 10. Liver weight g/kg of body weight
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b) Whole brain weight comparison is presented in Table 8.
Table 8. Brain weight (g) comparison in both groups
Group

Mean

Std.
Deviation

P-value
t-test
0.81

Placebo

39.1450

4.3852

Treatment

38.7263

2.2

Wilcoxon
score
0.07

Wilcoxon score-rank test revealed a p -value of 0.07, which indicates possible
significance if repeated with more subjects.
c) Cerebellar weight (g) comparison is illustrated in Table 9.
Table 9. Cerebellar weight (g) comparison in both groups
Group

Mean

Std.
Deviation

P-value
Student’s
t-test

Wilcoxon
score

0.8

1

Placebo

4.92

0.39

Treatment

4.98

0.76

d) Heart weight (g/kg) are reflected in table 10.
Table 10. Heart weight (g/kg) in both groups
Group

Mean

Std.
Deviation

P-value
Student’s
t-test

Wilcoxon
score

0.4

0.1

Placebo

9.28

1.53

Treatment

9.83

1.0

e) Pancreas weight (g/kg) (Table 11).
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Table 11. Pancreas weight (g/kg) in both groups
Group

Mean

Std.
Deviation

P-value
Student’s
t-test

Wilcoxon
score

0.2

0.5

Std.
Deviation

P-value
Student’s
t-test

Wilcoxon
score

0.5

0.2

Placebo

1.15

0.61

Treatment

1.24

0.34

f) Spleen weight (g/kg) (Table 12).
Table 12. Spleen weight (g/kg) in both groups
Group

Mean

Placebo

4.385

0.63

Treatment

5.11

1.59

g) Comparison of lung weight (g/kg) between groups (Table 13).
Table 13. Lung weight (g/kg) in both groups
Group

Mean

Std.
Deviation

P-value
Student’s
t-test

Wilcoxon
score

0.56

0.4

Placebo

16

2.9

Treatment

17.8

4.8

h) Kidney weight g/kg (Table 14).
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Table 14. Comparison of kidney weight (g/kg) between groups
Group

Mean
kidney

Std.
Deviation
kidney

P-value
t-test

right

left

right

left

right

left

Wilcoxon
score
right left

Placebo

4.48

4.6

2

2.1

0.2

0.2

0.1

Treatment

3.44

3.7

0.49

0.26

0.1

Body composition analysis
a) Body fat percentage
The percentage of body fat was significantly lower in treatment pigs [(placebo 10.8 ± 1.29 vs.
treatment 9.7 ± 0.89, n=16; p=0.05)].

p < 0.05

Figure 11. Body fat percentage treatment vs. placebo group
b) Body fat mass (g)
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The DEXA assessment reveled a significantly larger fat mass (g) in placebo pigs
[(placebo 401 ± 69.5 vs. treatment 268.2 ± 91.7, n=16; p=0.0157)], which was also significant
when normalized to body mass (g/kg) [(placebo 120.6 ± 18.79 vs. treatment 99.49 ± 10.1, n=16;
p=0.0157)].

p < 0.0157

Figure 12. Body fat mass (g) treatment vs. placebo group
c) Lean mass percentage between groups
Statistical analysis revealed a trend for a greater percentage of lean mass in treatment pigs
[(placebo 0.878 ± 0.014 vs. treatment 0.889 ± 0.0079, n=16)]. However, the difference did not
achieve significance (p< 0.07).
Table 15. Summary of lean mass percentage statistics in treatment vs. placebo
Group
Placebo

Mean

Median

Std. Deviation

0.878

0.880

0.014

Treatment

0.889

0.888

0.0079
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d) Lean mass between groups
Lean body mass grams [(placebo 3230.2 ± 385.7 g vs. treatment 2411.6 ± 616.4 g, n=16
p< 0.7)] and lean body mass g/kg [(placebo 983.7 ± 209.3 vs. treatment 908.6 ± 38.2, n=16 p<
0.7)]

p < 0.7

Figure 13. Distribution of lean body weight (g) between groups
e) Bone mineral content (BMC) (g) and bone mineral density (BMD) (g/cm²) analysis
Results of statistical analysis determined greater BMC and BMD in placebo group. It is
associated with greater body weight. BMC: [(placebo 47.67 ± 6.5 g vs. treatment 34.0 ± 5.9 g,
n=16; p<0.0007)], BMD: [(placebo 0.13 ± 0.00659 g/cm² vs. treatment 0.1258 ± 0.129 g/cm²,
n=16; p<0.0007)]. Pearson correlation analysis in Fisher’s z transformation determined that there
is correlation between weight (g) and BMC (g) (p-value < 0.002), therefore we can conclude that
higher BMC can be explained simply by larger size and it is not associated with dietary
intervention.
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p < 0.0007

p < 0.0007

Figure 14. BMC (g) and BMD (g/cm²) in treatment vs. placebo group
Blood biochemistry analysis
Basic metabolic parameters were compared using blood samples collected immediately
before death for the placebo group (n=8) and treatment group (n=8). The placebo pigs had higher
serum albumin, alanine aminotransferase, lactate dehydrogenase, total protein, and triglycerides.
Table 16. Summary of blood analysis
Group

ALB

g/dL
Treatment 2.2
Placebo
2.77
P-value
0.0077

ALP
U/L
431
589
0.1

ALT
U/L
11
20.1
0.049

AST
U/L
27.6
27.6
1

Ca
mg/dL
9.2
9.4
0.855

Chol.
mg/dL
79
76.8
0.68

CK
U/L
324
469
0.09

Creat.
mg/dL
0.69
0.62
0.266

LDH
U/L
375.8
574.6
0.002

TP
g/dL
3.7
4.03
0.03

TG
mg/dL
52.12
38.6
0.07

DISCUSSION
There is increasing evidence that SGA neonates are prone to metabolic abnormalities and
experience chronic disorders. Currently, there is no successful nutritional strategy that can
prevent health-related issues in SGA infants. This research is novel by determining if a
combination of functionally active nutrients can influence body composition and potentially
improve growth of SGA infants.
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Consequence of being SGA at birth. Baseline data collection included organ weights and
blood of SGA and AGA newborn term pigs. The analysis of organ weights revealed significant
differences for liver and spleen weights, with SGA pigs having significantly smaller livers and
spleens even after normalizing to body mass (g/kg). The growth and maturation of the brain and
cerebellum are of concern for SGA infants, but did not differ between newborn SGA and AGA
pigs. The differences in serum chemistries are suggestive of differences in liver functions, but
the specific issues were not determined.
Responses of SGA pigs to the supplement. Evaluating experimental dietary interventions
using SGA neonates is very difficult due to ethical considerations and may carry safety issues.
For this reason, newborn SGA pigs were used as a translational model for SGA neonates. This
model was previously validated as a credible model of a neonate in nutritional research (Lennon,
Zanganeh, & Borum, 2011; Svendsen & Koch, 2013).
During the dietary intervention, the treatment group was visually leaner, more active and
playful. In contrast, the placebo pigs after day 10 were less active, spent more time inactive, and
interacted less with the ball placed in the pen for enrichment.
Despite the fact that during the intervention both groups were provided similar amounts
of formula (~150 ml/kg/day), daily weight gains differed between the two groups. There are
several possible reasons. First, the treatment group was more active. Second, placebo pigs had a
greater amount of fat body mass. On the other hand, enteral leucine enhances muscle protein
synthesis in neonatal pigs by activating the mTOR pathway (Columbus, Fiorotto, et al., 2015;
Suryawan et al., 2008).
DEXA results confirmed that there were significant differences in body composition.
Placebo pigs were significantly larger, mostly because of greater accumulation of body fat.
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Treatment pigs had significantly smaller amounts of fat mass. This result fully corresponds with
SGA pediatric research studies (Ibáñez, Ong, Dunger, & de Zegher, 2006; Monteiro & Victora,
2005; Ong et al., 2000).
Organ development in SGA neonates is delayed compared to AGA infants. Moreover,
similar to premature infants, SGA infants experience catch-up growth period (Cho & Suh, 2016).
Analysis of collected organ weights during the study, revealed significantly larger livers of
placebo pigs. Recent studies have reported that being born SGA per se is an important risk
factor for non-alcoholic fatty liver disease (NAFDL) (Alterio, Alisi, Liccardo, & Nobili, 2014;
Nobili et al., 2007). Rapid weight gain is a major risk factor for later development of metabolic
complications, and has been implicated in the presence and severity of NAFLD in both children
and adults (Nobili et al., 2013). The larger livers of the placebo pigs had areas of discoloration
with that were not seen in the livers of treatment pigs. Moreover, ALT levels in placebo group
were two-fold higher than for treatment pigs (20.1 ± 10.7 vs. 11 ± 2.39; P=0.049). The larger
livers and higher liver enzyme activities in the serum may be indicative of early liver damage.
Although SGA infants can have differences in brain structure, compared to AGA
neonates and there is also catch-up growth period of cranial structures (Radlowski et al., 2014).
However, collected brain weights after 20 days of feeding did not differ between groups.
Summarizing all the results of the study, we can conclude that current supplement
composition is safe for use and improves body composition in SGA piglets by decreasing fat
deposition.
CONCLUSIONS AND RECOMMENDATIONS FOR FURTHER RESEARCH
Considering metabolic risks of individuals who were formerly SGA infants, efficient
dietary supplementation during early postnatal life is essential for growth and development that
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promotes quality of life. The data reported herein formula with a combination of MCT oil, krill
oil and leucine could improve body composition and growth of newborn piglets. Treatment
group was significantly leaner, more active than placebo group.
Although, brain weights were not significantly different between groups, the lack of
difference may be related to the relatively small sample size. Corresponding with this some
organ weights, such as the spleen and kidneys were trending to be significant levels between
groups. Therefore, for the future research, larger sample sizes will be needed.
Future studies should include immunohistochemistry analyses and labeling of
proliferating cells with 5-bromo-2'-deoxyuridine (BrdU). A longer period of study may be
recommended. Finally, the responses of AGA pigs to the same placebo and supplement should
be assessed.
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1) Randy Buddington, Marie van der Merwe, Samantha Davis, Lauren Wells, Kristy Levin,
Thomas Wong, Mitchel Penninger, Taisiya Yakimkova. All of these individuals have
taken the animal training course prior to participating. All of the personnel are actively
participating in our studies using small for gestational age pigs.
2) Karyl Buddington and Donny Ray: veterinarian and facility manager, both with extensive
experience in swine research
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Each year, more than 20 million infants worldwide are born with low birth weight (LBW).
These babies are often called being small for gestational age (SGA), which by definition means
that they are born in the lower 10% of birth weights. For term infants this is ~1.5 kg or babies
born at ~3.5 pounds and less. These SGA babies have an increased risk of death and disability.
There is increasing information about the differences and long term consequences between
infants born SGA and those born of appropriate weight for gestational age (AGA). This includes
compromised brain growth and development of SGA infants. Other organs are impacted by an
infant being SGA. These differences are associated with lifelong effects.
Studies with SGA human infants are extremely difficult due to obvious ethical
considerations. In the light of this fact, there is a need for animal models to understand the impact
of being SGA and to evaluate possible interventions. The neonatal piglet is a highly tractable
translational animal model that has been successfully used for SGA studies.
What is critical for the SGA infant is to provide nutrition support that will promote growth
and normal development. Currently, providing breast milk is considered the best approach.
However, breast milk is not available for all SGA infants and in reality may not be good enough.
The breast milk fed to many SGA infants is fortified with protein to encourage better growth.
Although this does improve gain in weight, most of the gain is fat, not lean body mass, and this
increases the risk of obesity, metabolic syndrome, cardiovascular disease, and other health issues
later in life. There is a need to improve nutrition support for the SGA infant to improve outcomes.
Our previous studies with preterm SGA pigs showed how supplementing formula
increased weight gain dramatically, and without an apparent increase in the amount of fat. We
also know that SGA infants have a need for essential fatty acids, and particularly long chain
omega 3 fatty acids, such as those in fish oil. These findings led us to the concept of a supplement
consisting of different nutrients that can be added to breast milk or existing infant formula that
will improve growth by increasing gain in lean body mass and will promote normal development.
We will determine if newborn term pigs that are SGA will benefit when they are fed
formula with the supplement by comparing them with those that don’t receive the supplement.
This will be accomplished by measuring growth, evaluating how much fat and lean body mass
they have using dual x-ray absorptiometry (known as DXA), performing serum chemistries, and
evaluating the growth and development of critical organs, including but not limited to the brain,
gut, kidneys, lungs, and immune system.
Our objective is to learn how to improve nutrition support for the SGA infant and then
work with neonatology colleagues and industry sponsors to translate our findings into improving
outcomes for babies that are SGA.

B. Describe IN DETAIL the procedures you will follow. Include accompanying
documentation and reference to previously published work in the box below. Provide a complete
bibliographic citation and describe any variations from the published technique. The
bibliography may be included in the box below or appended to this protocol.
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We will obtain newborn term pigs at <24 h of age with body weights of <800 g and are
considered as SGA. Additional pigs of average weight at term (1,200 – 1,600) will be used as
controls. All of the pigs will originate from the same commercial producer that supplies the sows
we use for our preterm pig studies. The newborn pigs will be allowed to suckle the sow until they
are brought to UM. Once at UM the pigs will be fed a commercial milk replacer (formula) for
pigs that meets or exceeds known nutrient requirements for suckling pigs.
The pigs will be housed in facilities specifically designed for care and handling preterm
and newborn term pigs, and which we have used previously for such studies. We request
approval to house the pigs in incubators with square footage that is smaller than what is listed for
housing pigs, but large enough to allow for free movement and activity. The incubators have
dimensions of 2’ x 4’ and have a slatted floor which will facilitate cleaning. The incubators will
have heating lamps to keep the pigs warm, like the heating lamps used to keep preterm infants
warm. Housing the pigs in the incubators is like keeping infants in cribs, and will enhance our
ability to feed and monitor the pigs individually. From our previous studies we know that the pigs
will huddle together for most of the time. The pigs will be observed and fed throughout the day
(minimum of 7 times. At each time the pigs will be fed, the caging cleaned, and health status
recorded. The pigs will be weighed a minimum of two times each day which will be an important
indicator of health and well-being. Additional observations will be made of general activity and
responsiveness to touch.
The SGA pigs will be fed the milk replacer for up to 20 days. Some pigs will be studied
earlier than 20 days to determine the responses at earlier time points. The supplement (or
placebo) will be added to the milk replacer. The supplement will include nutritional ingredients
that previous studies (our own and from the literature) have shown are likely to improve growth
and development. Our studies will use different combinations rather than single ingredients to
obtain synergistic benefits. During the project period we will try different combinations. The
ingredients to be evaluated as components of the supplement will include fatty acids, lipids, amino
acids, proteins, carbohydrates, and vitamins and minerals. The placebo will include other forms
of the same nutrients that are not considered to provide benefit. For examples, we will use alanine
rather than leucine, vegetable oil rather than fish or krill oil, maltodextrin rather than fermentable
fiber.
Blood will be collected from each pig one or two times during the period of feeding. This
will be accomplished by first anesthetizing the pig with isoflurane and while they are anesthetized
place them on their back to access the subclavian vein. We have done this previously with
newborn and juvenile pigs. If our findings suggest that more frequent blood sampling is desirable,
we will have jugular catheters surgically placed using the same surgical approach that we use for
our other studies using pigs with jugular catheters. The catheters will be used to collect blood
samples for analysis during the feeding period, to inject bromydeoxyuridine and puromycin
(below), and to administer euthanasia (euthasol). Pigs with jugular catheters will be housed
individually in the plastic tubs we used to house the pigs for our studies of short-bowel syndrome
that also required individual housing.
We will inject pigs with a combination of BrdU (50 mg/kg) and puromycin (18.8 mg/kg;
0.04 mmol/kg) 30 – 60 min prior to euthanasia. The BrdU is used to label cells that are
proliferating as an indicator of growth. The puromycin labels proteins that are being synthesized
as a secondary indicator of growth, with the emphasis on the increase in protein synthesis and lean
body mass. The BrdU and puromycin will be administered via the jugular catheter, if one is in
place. Pigs without jugular catheters will be sedated with telazol then placed under gas anesthesia
so the BrdU and puromycin can be administered via the subclavian vein. While these pigs are
anesthetized they will be imaged using dual x-ray absorptiometry (DXA) to assess the percentage
of lean and fat body mass. These pigs will remain under anesthesia for 30 min after the
administration of BrdU and puromycin until blood is collected for analysis followed immediately
by the administration of euthasol. This approach will avoid the need to use anesthesia twice.
After death each pig will be necropsied and organs will be removed, observed, weighed
and tissues collected for analysis.
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C.

Rationale for Involving Animals and the Appropriateness of Species and Number Used.

Indicate (here) briefly the short and/or long-term benefits (to humans and/or other animals) of
this use of animals for research, teaching or demonstration. Provide rational for and the number
of animals to be used. In addition, state briefly why living animals are required for this study,
rather than some alternative model.
There are no non-animal models that allow us to study if and how SGA pigs respond to nutrition
support protocols that could be used for preterm and term infants that are also SGA.
The pig is considered as a clinically relevant animal model for research focused on the
preterm and term infant. Alternative animal models (neonatal rats and mice) are available, but
because of small size and characteristics that differ from human infants, rodent models have
limited use for the proposed research because they are not considered translational. Although nonhuman primates would be suitable, they do not provide benefits beyond those available from
preterm pigs. Lambs are not appropriate because of differences with humans for organ structure
and development and feeding habits, they are seasonal breeders, and SGA lambs are in limited
supply, are not available locally,
D.

Do the procedures described in B above, have the potential to inflict more
than momentary pain or distress (this does not include pain caused by
injections or other minor procedures)?
Yes

No

I have considered alternatives to procedures that might cause more than momentary or slight
pain/distress, and I have not found such alternatives. As such, I have used one or more of the
following methods and sources to search for such alternatives: (check below each method used)
Agricola Data Base
TOXLINE

Medline Data Base
BIOSIS

CAB Abstracts
Lab. Animal Sci. Journal

Lab. Animals Journal

Lab Animal

Animal Welfare Info Center

ATLA (Alternatives to Laboratory Animal Journal)

Quick Biblio. Series

Lab Animal Welfare Bibliography (QL55L27311988)

"Benchmarks"

"Alternatives to Animal Use in Research, Testing and Education"
Current Contents
CARL
Direct contact with colleagues (if selected, you MUST document this below)

List search words for the literature search:
SGA, small for gestational age, pig, nutrition, preterm, neonate, infant, nutrition, formula

48

What is the length of time that the literature search covers?
1990 – 2016 (present)
III. Animal Use
A.

List all animal species to be used (example below).

Species

Number1 Age2

Sex2

Weight2

pig

80 per year

neonate

both

500-800 g

Where Housed
(Bldg./Rm#)
Fieldhouse 135

Pig

20 per year

neonate

Both

1,200 – 1,800

Fieldhouse 135

1Individuals
2Individuals

using ectotherms need to only approximate numbers.
using fish or other ectotherms need not answer this question.

Is any species threatened or endangered?
B.

Yes

No

Source of animals
Commercial vendor (Source_________ Prestage Farms, MS___________)
Bred at The University of Memphis
Captured from wild. Identify method of capture:
Transferred from another study (IACUC Protocol Number

)

Donated (Source

)

Tennessee Wildlife Resources Agency
Is the supplier a USDA approved source?

Yes

No

If not, explain why: The pigs will be obtained from Prestage Farms. This is a closed production
facility that maintains strict biocontainment to maintain specific pathogen free conditions.
The sows that produce the pigs are of the same genetic lineage.
Animals are already in residence at U of M
C.

Will surgery be conducted on animals?

Yes

No

If yes, complete this section:
Non Recovery Surgery
Recovery Surgery
Multiple Survival Surgery (if the latter is checked, complete section F)
Surgeon(s) (Name/Job/Title/Academic Rank)
Karyl Buddington or her designee

Location of Surgery (Bldg. & Room #)
422 Psychology
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Will Anesthetic(s), Analgesic(s), or
Tranquilizing agents be administered?

Yes

No

If yes, complete this section (example below).
Species & Sex

Agent

Dose

Route

Performed by
(Name/Title/Academic Rank)
K. Buddington or designee

Pig

Isoflurane

1-2%

Inhal.

Pig

Telazol

0.04 mg/kg

IM

K. Buddington or designee

Pig

Rimadyl

0.5 ml/pig

IM

K. Buddington or designee

Pig

Meloxicam

0.5 ml/pig

oral

K. Buddington or designee

E.
Will euthanasia be carried out?
If yes, complete this section (example below).
Species & Sex
Pig

Agent

Euthasol or equivalent

Yes

Dose

Route

1 ml/4.5 kg (10 lb)

IV

No

Performed by
(Name/Title/Academic Rank)
K. Buddington or designee

If no, describe disposition of animal(s) at conclusion of this study in box below.

F.

Will special housing, conditioning, diets or other conditions
be required?

If yes, please explain in box below.
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Yes

No

Most of the pigs will be group housed in plastic pens that are 2’ x 4’ sq. ft. that we have
used successfully for housing of 4-6 newborn term pigs. Pigs that have jugular catheters will need
to be housed individually in plastic pens of 1.5’ x 2.5’. The pens will be provided with heating
lamps.
The pigs will be trained to feed from the bottles with nipples. This will allow the pigs to
feed themselves and for the research team to monitor consumption.
We are requesting and exemption from the square footage recommended in 8th Edition of
the Guide for the Care and Use of Laboratory Animal, which suggests 6 sq ft per pig when pigs
<15 kg are housed in groups of 2-5 pigs. We seek an exemption for using housing with smaller
dimensions since the pigs are not expected to reach more than 5-6 kg. Based on our previous
studies using the same pens, the amount of available space will does not impair movement and
provided enough space for the pigs to freely move and play. When groups housed in the larger
pens, we request permission for a maximum of 6 pigs in each of the pens. Pigs to be housed
individually will be kept in the smaller pens.

G. Will animals be removed from the U of M campus at any time?
If yes, please indicate to where and for how long in box below.

Yes

No

H. If they are to be housed for more than 24 hours outside approved facilities at U of M,
provide a scientific justification in box below.

IV. Toxic and Hazardous Substances
A.

Check off any of the following below that will be used in these experiments?
Infectious agents (Fill out a, b)
Radioisotopes (Fill out a, b, e)
Toxic chemicals or carcinogens (Fill out a, b)
Recombinant DNA (Fill out a)
Experimental drugs (Fill out a)
Malignant cells or hybridomas (Fill out a, c)
Adjuvants (Fill out a)
Controlled substances (Fill out a, d, e)

For each checked off category, answer the questions indicated below:
a.

Identify the substance(s) and completely describe their use, including how will be injected
or given to the animal(s):

51

We will use Euthasol (or equivalent) to euthanize the experimental pigs (1 ml/4 kg; IV). The
bromydeoxyuracil (BrdU) and puromycin will be administered IV via subclavian access and used
to label proliferating cells as an indicator of growth responses. The BrdU will be prepared in a
fume hood located in room 231 of Smith Chemistry. This will be done by adding BrdU to sterile
0.9% saline at 10 mg/ml and using a sonicator to put the BrdU in solution. The BrdU solution will
be drawn up into a syringe just prior to administration. Preparation of the BrdU will be done by R.
Buddington or his trained designee.
The puromycin will be purchased as a powder and added to 0.9% sterile saline for IV
administration via the subclavian vein.
The euthasol solution will administered via the jugular catheter, if present, or via cardiac
puncture or IV via the subclavian vein.
The Telazol and Rimadyl will be administered IM. The meloxicam will be given orally.
b.

Describe all procedures necessary for personnel and animal safety including biohazardous
waste, carcass disposal and cage decontamination:

The Euthasol, bromydeoxyuracil, puromycin, Rimadyl, and Telazol will be administered using a
syringe to avoid contact with project personnel. The resulting carcasses will be disposed of by
incineration. There will be no cage contamination.

c.

If transplantable tumors or hybridoma cells are to be injected into the
animals, have the tissues/cells been tested for inadvertent contamination
by viruses or mycoplasma?
Yes

No

If yes, what was the result (indicate in box below).

d.

In the box below, provide a complete list of these substances, and if their use is not
explicitly explained in the materials already provided, explain their use and role in the
research.

Provide DEA license # covering the use of these substances: BB9988847
To whom (or what entity) is the license issued? Karyl K. Buddington
e. Provide Radioisotope License Number:
To whom is the license issued?
V.

Categories of Animal Experimentation Based Upon Level of Manipulation and Pain:
(check off each category that is applicable to this application)
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Animals will be involved in teaching, research, experiments or tests involving
distress, or use of pain-relieving drugs.

no pain,

B.

Animals will be subject to mild stress only (e.g., food or water deprivation of less
than 24 hours for use in behavioral studies such as operant conditioning; physical
restraint for less than 30 minutes), and will not be subject to surgery, painful stimuli,
or any of the other conditions described below. Procedures described in this protocol
have the potential to inflict no more than momentary or slight pain or distress on the
animal(s)----that is, no pain in excess of that caused by injections or other minor
procedures such as blood sampling.

C.

Animals will have minor procedures performed, blood sampling, etc. while
anesthetized.
The majority of pigs will not have surgeries for placement of jugular catheters and
are appropriate for this category.

D.

Live animals will be humanely killed without any treatments, manipulations, etc. but
will be used to obtain tissue, cells, sera, etc.

E.

Live animals will have significant manipulations, surgery, etc. performed while
anesthetized. The animals will be humanely killed at experiment termination without
regaining consciousness.

F.

Live animals will receive a painful stimulus of short duration without anesthesia
(behavior experiments with flight or avoidance reactions--e.g., shock/reward)
resulting in a short-term traumatic response. Other examples in this category are,
blood sampling, injections of adjuvants, or drugs, etc.

G.

Live animals will have significant manipulations performed, such as surgery, while
anesthetized and allowed to recover. Such procedures cause post-anesthetic
pain/discomfort resulting from the experiment protocol (e.g., chronic catheters.
surgical wounds, implants) which cause a minimum of pain and/or distress. Also
included are mild toxic drugs or chemicals, tumor implants (including hybridomas).
tethered animals, short-termed physically restrained animals (up to 1 hour),
mother/infant separations.
This applies to the pigs that will have surgery to place jugular catheters.

H.

Live animals will have significant manipulations or severe discomfort, etc. without
benefit of anesthesia, analgesics or tranquilizers. Examples to be included in this
category are: toxicity testing, radiation sickness, irritants, burns, trauma, biologic
toxins, virulence challenge, prolonged: restrictions of food or water intake, cold
exposure, physical restraint or drug addiction. All use of paralytic agents (curare-like
drugs) must be included in this category. Describe any abnormal environmental
conditions that may be imposed. Describe and justify the use of any physical restrain
devices employed longer then 1 hour.

VI. Justifications for Category G Studies and Deviations from Standard Techniques
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Describe in the box below any steps to be taken to monitor potential or overt pain and/or distress
during the course of this study and how such pain or distress will be alleviated. Be as detailed as
necessary to justify your procedure.
Pigs that require surgery for placement of a jugular catheter will be fully anesthetized for the
surgery. Rimadyl will be administered before the pigs recover from surgery to provide analgesia.
Meloxicam will be provided the day after surgery for analgesia.
VII. Certifications
(By submitting this protocol, I am acknowledging that I comply with the certifications
included in Section VII.) (check one)
Animal Use for Research. I certify that the above statements are true and the protocol
stands as the original or is essentially the same as found in the grant application or
program/project. The IACUC will be notified of any changes in the proposed project, or
personnel, relative to this application, prior to proceeding with any animal experimentation.
I will not purchase animals nor proceed with animal experimentation until approval by the
IACUC is granted.

Animal Use for Teaching/Demonstration. I certify that the information in this application is
essentially the same as contained in the course outline and a copy of the laboratory
exercises using animals is on file in the IACUC office. The IACUC will be notified of any
changes in the proposed project, or personnel, relative to this application, prior to
proceeding with any animal experimentation. I will not proceed with animal
experimentation until approval by the IACUC is granted.
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Estimate the cost of maintaining animals used in this protocol based on current per diem charge
at University of Memphis.
Please specify cost per unit of time:

$ 1,000 per month

Specify anticipated total costs for project duration:

$ 3,000

As supervisor of this project it is required that you inform your department chair
concerning any animal per diem costs related to this project that are to be paid by the
department.
By submitting this protocol, the Principal Investigator/Course Director indicates that the
following have been considered:
1.
2.
3.
4.
5.
6.

7.

Alternatives to use of animals.
Reduction of pain and stress in animals to the lowest level possible.
The proper needs of the animals with respect to housing and care.
The lowest number of animals used that will give the appropriate experimental results.
Use of the most primitive species that will give the appropriate experimental results.
Proper training of all personnel in the care and handling of the species used and in the
procedures called for in this protocol before beginning the experiment/teaching or
demonstration.
That this protocol is not an unnecessary repeat of results already in the literature or in the
case of teaching/demonstrations, results that can be demonstrated using models or video
material.

Principal Investigator/Course Director (Type Name) Randal K. Buddington
e-mail address rbddngtn@memphis.edu
Date

12-1-2016

Federal Law requires that members of the IACUC be given adequate time to read and review
protocols including any changes or revisions in them.
Pre-review of protocols by the Attending Veterinarian is required before submission to the
IACUC. New protocols or modifications or renewals to protocols must be submitted to the
IACUC Chair by the 1st business day of the month to be considered for review during that
month. Incomplete protocols will be returned to the principal investigator.
E-mail the completed protocol to the IACUC Chair, Dr. Amy de Jongh Curry,
adejongh@memphis.edu

February, 2015
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